Products - Business To Business

Disclaimer: Availability of products is subject to patent restrictions in countries where applicable patents are in effect.

Download PDF
Product Name Strength and Dosage form Brand/Innovator Indication Dossier Availability
ENZALUTAMIDE 40mg, 80mg Film-coated tablets Xtandi® (Astellas) Prostate cancer Q3-2026
PAZOPANIB (as hydrochloride) 200mg, 400mg Film-coated tablets Votrient® (Novartis) Renal cell cancer YES
BARICITINIB 1mg, 2mg, 4mg Film-coated tablets Olumiant® (Eli Lilly) Rheumatoid arthritis Q4-2026
EMPAGLIFLOZIN 10mg, 25mg Film-coated tablets Jardiance® (Boehringer) Type 2 - Diabetes Mellitus Q1-2026
EMPAGLIFLOZIN / LINAGLIPTIN 10mg/5mg, 25mg/5mg Film-coated tablets Glyxambi® (Boehringer) Type 2 - Diabetes Mellitus Q3-2026
EMPAGLIFLOZIN / METFORMIN 5mg/850mg, 5mg/1000mg, 12.5mg/850mg, 12.5mg/1000mg Film-coated tablets Synjardy® (Boehringer) Type 2 - Diabetes Mellitus Q3-2026
LINAGLIPTIN 5mg Film-Coated Tablets Tradjenta® (Boehringer) Type 2 - Diabetes Mellitus YES
LINAGLIPTIN / METFORMIN 2.5mg/850mg, 2.5mg/1000mg Film-Coated Tablets Jentadueto® (Boehringer) Type 2 - Diabetes Mellitus Q4-2025
SITAGLIPTIN (as Hydrochloride monohydrate) 25mg, 50mg, 100mg Film-coated tablets Januvia® (Merck Sharp & Dohme) Type 2 - Diabetes Mellitus YES
SITAGLIPTIN (as Hydrochloride monohydrate) / METFORMIN HYDROCHLORIDE 50mg/850mg, 50mg/1000mg Film-coated tablets Janumet® (Merck Sharp & Dohme) Type 2 - Diabetes Mellitus YES